Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

May 24, 2025
Speakers: Scott Furlan, MD, PhD, Daniel J. DeAngelo, MD, PhD

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston. They discuss a phase I study with recent results that point to a potentially significant advance in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists

May 16, 2025
Speakers: Michael Scott, MD, and Marc Michel, MD, MSc

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Support for this episode provided by Autolus.

No Scientific Link Found Between Sickle Cell Trait and Sudden Death

April 28, 2025
Speakers: Samuel Wilson, MD, MSCR and Michael DeBaun, MD, MPH

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Excellence. They talk about a systematic literature review, led by Dr. DeBaun and published in the journal Blood, that found no link between sickle cell trait and sudden death – a finding that challenges a long-standing myth about the trait. Support for this episode provide by Siemens Healthineers.